Although this theoretically impairs effector T cell activity, for primary drug-resistant tumor cells with low PD-L1 and Fas/CD95 expression, inhibiting glutamine metabolism alongside anti-PD-L1 therapy can significantly enhance T cell antitumor activity [334]. This evidence concerns the gene FAS and neoplasm.